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Abstract
Background: Recently, a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) has been developed
as an international and standardized brief cognitive test, which is easily performed in everyday clinical practice for
neuropsychological assessment in multiple sclerosis (MS). However, we need to gather more information about this
tool compared to other neuropsychological batteries. The aim of our study is to compare the performance of BICAMS
and Brief Repeatable Battery (BRB) in MS subjects.
Methods: Tests of the BRB and BICAMS were administered to MS patients recruited from 11 Italian MS centres.
Cognitive impairment (CI) was defined as the failure on at least two tests (scores below the fifth percentile) on
the BRB and as the failure on at least one test of the BICAMS. The agreement between the performances on the
two batteries was assessed through Cohen’s K statistic. Finally we calculated the effects sizes for each test of the
two batteries using Cohen’s d.
Results: The two batteries were administered to 192 MS patients (142 women, 50 men; mean age 41.4 ± 10.8 years,
mean education 12.3 ± 3.5 years). Mean scores of patients were lower compared to those of healthy subjects in all the
cognitive measures examined. Forty-six MS patients were identified as impaired and 48 as unimpaired on both of the
batteries, when the Symbol Digit Modalities Test (SDMT) was included in the analysis. Cohen’s K statistic was 0.46
which corresponds to a moderate accord. If the SDMT was excluded from the BRB, 37 MS patients were identified as
impaired and 57 as unimpaired on both of the batteries. Cohen’s K statistic was 0.3 which corresponds to a poor
accord. The SDMT, the Paced Auditory Serial Addition Test (PASAT) 3 and 2 yielded higher d values (SDMT 0.83, PASAT
3 0.65, PASAT 2 0.84).
Conclusions: This study confirms the feasibility of BICAMS in everyday clinical practice for the identification of CI and
highlights the good psychometric properties of the SDMT.
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Background
Cognitive impairment (CI) affects about 40–60 % of
multiple sclerosis (MS) subjects [1]. It involves all the
disease subtypes and it can be documented from the
very beginning of the disease [1, 2]. Once established, it
tends to progress over time, sometimes independently
from the accumulation of physical disability [1]. Deficits
of complex attention, information processing speed, epi-
sodic memory and executive functioning are prominent,
whereas language and general intelligence are usually
spared [3]. Also independently of physical disability, CI
can have an important negative impact on patient
performance in everyday activities, employment, social
and recreational activities [1]. For this purpose, assess-
ment of MS-related CI is strongly recommended. The
most commonly used instrument to estimate cognitive
dysfunction in MS patients, both for clinical practice
and research purposes, is the Brief Repeatable Battery
(BRB), that includes cognitive domains most frequently
affected [4]. Normative values in the Italian population
are available [5]. Despite its good psychometric proper-
ties, the implementation in clinical practice is limited by
its time-consuming nature (about 45 min) and the need
of administration and interpretation by experienced
neuropsychologists. Therefore, there has been consider-
able effort over the past decade to streamline the neuro-
psychological assessment in MS, by developing brief
assessment tools that can be incorporated in everyday
patient assessment. In particular, recently, a Brief Inter-
national Cognitive Assessment for MS (BICAMS) has
been recommended as an international, validated and
standardized brief cognitive test [6]. It is easily per-
formed in everyday clinical practice as it can be com-
pleted in 15 min and can be administered by health care
professionals who are not cognitive specialists. No special
equipment (beyond pen, paper and stopwatch) is required
[6, 7]. Translation and validation of the BICAMS is on
going in several countries. It has been recently validated in
the American [7], Czech [8], Iranian [9] and Italian popu-
lations [10]. We can consider BICAMS as a brief, practical
and universal assessment tool for CI in MS subjects.
However, little is known on its performance in compari-
son to other neuropsychological batteries. For this pur-
pose, the aim of our study is to compare the performance
of BICAMS and BRB as screening tools for cognitive
impairment in MS patients [5, 10].
Methods
A total of 192 MS patients (142 women; 50 men), among
those consecutively admitted to some of the major
Italian MS centres (Bari, Barletta, Bologna, Cagliari,
Chieti, Florence, Gallarate, Lanciano, Milan, Naples and
Rome), were recruited. Inclusion criteria were diagnosis
of relapsing-remitting (RR) MS [11] and age >18 years.
Inclusion was restricted to RRMS subjects in order to
avoid heterogeneity of cognitive profile due to MS
course. Exclusion criteria were presence of current or
past neurological disorder other than MS, major psychi-
atric illness, history of learning disability, serious head
trauma, alcohol or drug abuse and relapse and/or cor-
ticosteroid use within 4 weeks preceding assessment. All
the subjects had adequate vision and hearing to undergo
the tests. All the participants in the study provided their
informed consent and the study was approved by the
ethic committee of the University of Florence.
Neuropsychological test procedures
At each site, patients were examined by the same neuro-
psychologist, who had participated to a common training
session, in order to ensure uniform administration, data
recording and scoring procedures. Tests of the BRB and
BICAMS were administered in a standardized manner,
during daytime, in a quiet room, and in a fixed order.
We first administered the BRB and subsequently the
BICAMS, in different sessions, within 1 week. The
SDMT [4] was given only once. We used the validated
Italian translation of both batteries [5, 10]. The BRB
incorporates tests of verbal memory acquisition and
delayed recall (Selective Reminding Test- SRT), visual
memory acquisition and delayed recall (10/36 Spatial
Recall Test-SPART), attention, concentration and speed
of information processing (Paced Auditory Serial
Addition Test –PASAT; SDMT) and verbal fluency on
semantic stimulus (Word List Generation-WLG) [4].
The administration of the whole BRB battery takes about
45 min. The BICAMS includes the SDMT [4], California
Verbal Learning Test, second edition (CVLT-II) first five
trials, for assessing verbal memory [12] and Brief Visuo-
spatial Memory Test-Revised (BVMT-R) first three recall
trials, for visual-spatial memory [13]. Administration of
the whole battery takes about 15 min.
Statistical analysis
Group comparisons were assessed through Student’s t
test, Mann–Whitney U test and χ2 test, as appropriate.
CI was defined as the failure on at least two tests (scores
below the fifth percentile) on the BRB, based on the
Italian normative data [5]. Failure on the BICAMS was
defined as the failure in at least one test of the battery
[10]. Performance on the SDMT was assessed using
normative data from the Italian BICAMS validation [10].
The agreement between the performances of the two
batteries was assessed through Cohen’s K statistic [14–16].
The sensitivity, specificity and accuracy of the BICAMS
against the BRB were assessed. Finally we calculated the
effects sizes for each test of the two batteries using
Cohen’s d (difference between means divided by pooled
SD) separating MS patients and controls [17].
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Results
The study sample consisted of 192 consecutive RRMS
patients from 11 Italian MS Centres (Table 1). Table 2
shows mean scores of patients and normative samples
on the neuropsychological tests [5, 10]. Mean scores of
patients were lower compared to those of healthy
subjects in all the cognitive measures examined. To
compare the performance on the BICAMS and the BRB,
we have repeated the analysis excluding SDMT, which
was the only neuropsychological test included in both of
the batteries. This exclusion is intended to avoid an
overestimation of the accord between the two assess-
ment tools. Forty-six MS patients were identified as
impaired and 48 as unimpaired on both batteries, when
the SDMT was included in the analysis. Cohen’s K
statistic was 0.46 which corresponds to a moderate
accord [14–16]. The Cohen’s K statistic estimating the
agreement between the SDMT alone and the BRB was
comparable (0.42). As expected, the concordance
decreased if we excluded the SDMT from the BRB. In
this case, 37 MS patients were identified as impaired and
57 as unimpaired on both of the batteries. Cohen’s K
statistic was 0,3 (0.26 for the SDMT alone) which corre-
sponds to a poor accord [14–16]. Using the whole BRB
as the gold standard, overall BICAMS sensitivity was
58,2 %, specificity 86,7 %, with an accuracy of 75 %.
Using the SDMT alone the sensitivity was 43 %, the
specificity 95,6 % and accuracy 73,9 %. Table 3 shows
Cohen’s d for different tests [17]. Overall, verbal memory
tests of the BRB and BICAMS were comparable (SRT-LTS
0.55, SRT-CLTR 0.61, CVLT 2 0.61). Instead, the BVMT-R
of the BICAMS showed a higher d value (0.60) as
compared with the SPART test (0.38). Finally, the SDMT,
PASAT 3 and 2 yielded higher d values (SDMT 0.83,
PASAT 3 0.65, PASAT 2 0.84).
Discussion
Cognitive assessment represents a key step in taking
charge of MS patients. The most widely used neuro-
psychological battery is BRB [5]. Recently the BICAMS,
a rapid tool, more suitable to be incorporated in every-
day patient assessment, has been developed [6]. We
Table 1 Characteristics of the study sample (# 192 MS subjects)
Age, years, mean (SD) 41.4 (10.8)
Education, years, mean (SD) 12.3 (3.5)
Gender (women, men) 142/50
Disease duration, years, mean (SD) 12.7 (8.9)
EDSS, mean (SD) 2.7 (1.7)
# of relapses in the year prior to inclusion, mean (SD) 0.5 (0.8)
Treatment with DMD, n (%) 154 (80.2)
MS multiple sclerosis, SD standard deviations, EDSS expanded disability status
scale, DMD disease modifying drugs
Table 2 Mean scores (SD) of patients and normative samples
on the neuropsychological tests [5, 10]
Test MS (#192) HC p
BRB
SRT-LTS 39.9 (14.4) 47.5 (13.1) <0.001
SRT-CLRT 31.3 (15.0) 40.3 (14.4) <0.001
SPART 18.9 (5.5) 20.9 (4.9) <0.001
PASAT-3 36.1 (15.7) 45.0 (10.6) <0.001
PASAT-2 25.6 (14.1) 36.5 (11.5) <0.001
SRT-D 7.9 (2.9) 8.9 (2.2) <0.001
SPART-D 6.4 (2.4) 7.2 (2.4) 0.002
WLG 23.4 (6.7) 26.1 (5.8) <0.001
BICAMS
SDMT 46.4 (12.8) 56.3 (11.3) <0.001
CVLT-II 49.9 (12.1) 56.3 (9.0) <0.001
BVMT-R 23.7 (8.0) 27.9 (6.1) <0.001
MS multiple sclerosis, HC healthy control, BRB brief repeatable battery, SRT-LTS
selective reminding test-long term storage, SRT-CLRT selective reminding
test-consistent long term retrieval, SPART spatial recall test, PASAT-3 paced
auditory serial addition test-3 s, PASAT-2 paced auditory serial addition test-2 s,
SRT-D selective reminder test-delayed, SPART-D spatial recall test-delayed, WLG
world list generation, BICAMS brief international cognitive assessment in multiple
sclerosis, SDMT symbol digit modalities test, CVLT-II California verbal learning
test-second version, BVMT-R brief visuospatial memory test-revised
Table 3 Cohen’s d for each test of the two batteries separating
MS patients and controls
Test d
BRB
SRT-LTS 0.55
SRT-CLTR 0.61
SPART 0.38
PASAT 3 0.65
PASAT 2 0.84
SRT-D 0.38
SPART-D 0.33
WLG 0.43
BICAMS
SDMT 0.83
CVLT-II 0.61
BVMT-R 0.60
BRB brief repeatable battery, SRT-LTS selective reminding test-long term storage,
SRT-CLRT selective reminding test-consistent long term retrieval, SPART spatial
recall test, PASAT-3 paced auditory serial addition test-3 s, PASAT-2 paced auditory
serial addition test-2 s, SRT-D selective reminder test-delayed, SPART-D spatial recall
test-delayed, WLG world list generation, BICAMS brief international cognitive
assessment in multiple sclerosis, SDMT symbol digit modalities test, CVLT-II
California verbal learning test-second version, BVMT-R brief visuospatial
memory test-revised
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recently published normative values for the BICAMS in
the Italian population [10]. The implementation of
BICAMS is still in its infancy; therefore we need to
obtain more information about its performance in com-
parison to other neuropsychological batteries. In the
present study we administered to MS patients both the
BRB and the BICAMS. Mean scores of patients were
lower compared to those of healthy subjects [5, 10] in all
the cognitive measures examined. This is in line with
the typical cognitive profile in MS patients [1]. In our
study, tests with higher discriminating ability according
to the d values were the SDMT, PASAT 2 and 3 s. This
finding is in line with recent literature, identifying the
SDMT as the test with higher ability in differentiating
MS patients from healthy controls [18, 19]. On the basis
of our results, the agreement between the BICAMS and
the BRB is fair to moderate and mainly dependent on
the inclusion of the SDMT, which is the only common
test between the two batteries. We can hypothesize that
the BICAMS and the BRB cannot be considered as
equivalent in the assessment of CI in MS. The BRB
investigates more comprehensively the cognitive profile,
including wider assessment than the BICAMS. There-
fore, we can consider the BRB a brief neuropsychological
battery more complete than the BICAMS and more suit-
able to identify change over time [20–22]. The BICAMS,
on the other hand, can represent a valid alternative to a
more comprehensive battery when available resources
are scarce. Since in our study cognitive evaluations were
performed by neuropsychologists, further analyses includ-
ing the administration of tests by health care professionals
who are not cognitive specialists are needed, in order to
confirm the external validity of our findings.
Conclusions
In conclusion, on the basis of our results, we can con-
sider the BICAMS a brief and feasible tool appropriate
for the cognitive assessment of MS patients and for re-
search use. It seems important to stress that, in optimal
clinical conditions, where a neuropsychologist can take
care of the cognitive assessment, it is preferable to
achieve a more thorough cognitive evaluation using tools
including neuropsychological tests that investigate sev-
eral cognitive domains impaired in MS.
Abbreviations
BICAMS: Brief international cognitive assessment for multiple sclerosis;
MS: Multiple sclerosis; BRB: Brief repeatable battery; CI: Cognitive impairment;
SDMT: Symbol digit modalities test; PASAT 3 and 2: Paced auditory serial
addition test 3 and 2; RR: Relapsing-remitting; SRT: Selective reminding test;
SPART: 10/36 spatial recall test; WLG: Word list generation; CVLT-II: California
verbal learning test, second edition; BVMT-R: Brief visuospatial memory
test-revised.
Competing interests
MPA received personal compensation from Merck Serono, Biogen, Genzyme,
Teva and Novartis for serving on scientific advisory board and for speaking,
received financial support for research activites from Almirall, Merck Serono,
Biogen Idec, Bayer Schering, Genzyme, Novartis, Genzyme and Teva. BG
serves on a scientific advisory board for Biogen, received honoraria for
speaking from Biogen-Idec and Teva. LP and MG received article grants from
Almirall and Biogen. MF has received travel grants from Fondazione Italiana
Sclerosi Multipla (FISM). EM has received travel and research grants from
Fondazione Italiana Sclerosi Multipla (FISM) and serves as consultant for
“Fondazione Cesare Serono”. RGV serves on a scientific advisory board for
Biogen. E Po serves on a scientific advisory board for Biogen, Merck Serono
and Bayer, received honoraria for speaking from Biogen-Idec and Teva, and
receives research support from Merck Serono. MT has received honoraria for
consultancy or speaking from Biogen, Sanofi-Aventis, Merck Serono and
Bayer-Schering and research grants from Merck Serono, Biogen and Novartis.
VM has received speaker honoraria or funding for travel expenses from
Biogen-Idec, Merck Serono, Bayer Schering, Novartis, Teva Pharmaceutical
Industries and Genzyme. UN has served as consultant for Biogen Idec, Sanofi
Aventis, Teva Pharmaceuticals, Novartis Pharma, Boehringer-Ingelheim and
has received travel and research grants by Merck Serono, Novartis Pharma
and Biogen Idec. GF has received honoraria for consultancy or speaking from
Merck Serono, Novartis and Teva. EC has received honoraria for consultancy
or speaking from Biogen, TEVA, Novartis, Sanofi-Aventis, Merck Serono and
Bayer. MGM has received honoraria for consultancy or speaking and research
grants from Biogen, Sanofi-Aventis, TEVA, Novartis, Merck Serono and Bayer.
EPi has received travel grants from Bayer Schering, Biogen Idec, Merck
Serono, Novartis, Sanofi-Aventis and TEVA and has also received travel and
research grants from the Fondazione Italiana Sclerosi Multipla. AL was a
Bayer, Biogen Idec, Merck Serono, Novartis and Genzyme Advisory Board
Member, received travel grants and honoraria from Bayer, Biogen Idec, Merck
Serono, Novartis, Sanofi and Teva and research grants from Bayer, Biogen
Idec, Merck Serono, Novartis, Sanofi and Teva, she also received travel and
research grants from the Associazione Italiana Sclerosi Multipla and was a
Consultant of “Fondazione Cesare Serono”. AG has served on scientific
advisory boards for Merck Serono, Novartis, Biogen Idec, Teva Pharmaceutical
Industries Ltd., and has received speaker honoraria from Merck Serono, Biogen
Idec, Bayer Schering Pharma, Sanofi-Genzyme, Novartis, Serono Symposia
International and Almirall. MR has received honoraria for consultancy from
“Fondazione Cesare Serono”.
CN, BH, IR, CI, EG, FIA, MM, MC, NAL, GBZ, LP, DC and SS have no competing
interests.
Authors’ contributions
CN and BG drafted/revised the manuscript, participated in study concept or
design and carried out acquisition of data. E Po and MPA drafted/revised the
manuscript, participated in study concept or design, analysis or
interpretation of data and carried out study supervision. BH, MG, LP, IR, MF,
EM, VM, CI, UN, GF, EC, MGM, EG, FIA, MM, MC, RGV, MT, NAL, GBZ, E Pi, AL,
LP, MR, AG, DC and SS participated in study concept or design and
acquisition of data. All authors read and approved the final manuscript.
Author details
1Department of NEUROFARBA, University of Florence, Largo Brambilla 3,
Florence 50134, Italy. 2Don Gnocchi Foundation, Florence, Italy. 3IRCCS
Hospital San Raffaele, Milan, Italy. 4University of Rome “Tor Vergata” c/o
I.R.C.C.S. “Santa Lucia” Foundation, Rome, Italy. 5University of Cagliari, Cagliari,
Italy. 6Hospital of Colli Monaldi Cotugno CTO, Naples, Italy. 7Hospital of
Lanciano, Lanciano, CH, Italy. 8University of Bari, Bari, Italy. 9Hospital of
Barletta, Barletta, Italy. 10Department of Neuroscience, Imaging and Clinical
Sciences, University “G. d’Annunzio”, Chieti, Italy. 11MS Centre, Hospital of
Gallarate, Gallarate, Italy. 12IRCCS Institute of Neurological Sciences, Bologna,
Italy.
Received: 18 March 2015 Accepted: 6 October 2015
References
1. Amato MP, Zipoli V, Portaccio E. Cognitive changes in multiple sclerosis.
Expert Rev Neurother. 2008;8:1585–96.
2. Zipoli V, Goretti B, Hakiki B, Siracusa G, Sorbi S, Portaccio E, et al. Cognitive
impairment predicts conversion to multiple sclerosis in clinically isolated
syndromes. Mult Scler. 2010;16:62–7.
Niccolai et al. BMC Neurology  (2015) 15:204 Page 4 of 5
3. Amato MP, Langdon D, Montalban X, Benedict RH, DeLuca J, Krupp LB,
et al. Treatment of cognitive impairment in multiple sclerosis: position
paper. J Neurol. 2013;260:1452–68.
4. Rao S. A manual for the brief repeatable battery of neuropsychological tests
in multiple sclerosis. Milwaukee: Medical College of Wisconsin; 1990.
5. Amato MP, Portaccio E, Goretti B, Zipoli V, Ricchiuti L, De Caro MF, et al. The
Rao’s brief repeatable battery and stroop test: normative values with age,
education and gender corrections in an Italian population. Mult Scler.
2006;12:787–93.
6. Langdon DW, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S, et al.
Recommendations for a Brief International Cognitive Assessment for
Multiple Sclerosis (BICAMS). Mult Scler. 2012;18:891–8.
7. Benedict RH, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S, et al.
Brief International Cognitive Assessment for MS (BICAMS): international
standards for validation. BMC Neurol. 2012;12:55.
8. Dusankova JB, Kalincik T, Havrdova E. Cross cultural validation of the
Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS)
and the Brief International Cognitive Assessment for Multiple Sclerosis
(BICAMS). Clin Neuropsychol. 2012;26:1186–200.
9. Eshaghi A, Riyahi-Alam S, Roostaei T, Haeri G, Aghsaei A, Aidi MR, et al.
Validity and reliability of a Persian translation of the Minimal Assessment of
Cognitive Function in Multiple Sclerosis (MACFIMS). Clin Neuropsychol.
2012;26:975–84.
10. Goretti B, Niccolai C, Hakiki B, Sturchio A, Falautano M, Eleonora M, et al.
The brief international cognitive assessment for multiple sclerosis (BICAMS):
normative values with gender, age and education corrections in the Italian
population. BMC Neurol. 2014;14:171.
11. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al.
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald
criteria. Ann Neurol. 2011;69:292–302.
12. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test,
second edition (CVLT-II). San Antonio: Psychological Corporation; 2000.
13. Benedict RHB. The Brief Visuospatial Memory Test Revised (BVMT-R). Lutz:
Psychosocial Assessment Resources Inc; 1997.
14. Fleiss JL. The measurement of interrater agreement. In: Statistical methods
for rates and proportions. NewYork: Wiley; 1981.
15. Fleiss JL. Measuring nominal scale agreement among many raters. Psychol
Bull. 1971;76:378–82.
16. Landis JR, Koch GG. The measurement of observer agreement for
categorical data. Biometrics. 1977;33:159–74.
17. Cohen J. Statistical power analysis for the behavioral sciences (second ed.).
Hillsdale: Lawrence Erlbaum Associates; 1988.
18. Strober L, Englert J, Munschauer F, Weinstock-Guttman B, Rao S, Benedict RH.
Sensitivity of conventional memory tests in multiple sclerosis: comparing the
Rao brief repeatable neuropsychological battery and the minimal assessment
of cognitive function in MS. Mult Scler. 2009;15:1077–84.
19. Drake AS, Weinstock-Guttman B, Morrow SA, Hojnacki D, Munschauer FE,
Benedict RH. Psychometrics and normative data for the multiple sclerosis
functional composite: replacing the PASAT with the symbol digit modalities
test. Mult Scler. 2010;16:228–37.
20. Amato MP, Razzolini L, Goretti B, Stromillo ML, Rossi F, Giorgio A, et al.
Cognitive reserve and cortical atrophy in multiple sclerosis: a longitudinal
study. Neurology. 2013;80(19):1728–33.
21. Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, et al.
Effects of immunomodulatory treatment with subcutaneous interferon
beta-1a on cognitive decline in mildly disabled patients with relapsing-
remitting multiple sclerosis. Mult Scler. 2010;16(1):68–77.
22. Amato MP, Portaccio E, Goretti B, Zipoli V, Battaglini M, Bartolozzi ML, et al.
Association of neocortical volume changes with cognitive deterioration in
relapsing-remitting multiple sclerosis. Arch Neurol. 2007;64(8):1157–61.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Niccolai et al. BMC Neurology  (2015) 15:204 Page 5 of 5
